GlassScriptPhysician profile
Ashley C Hepner
NPI 1871894329
$6,084.18
in general payments reported to CMS, 2019-2025
20 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $765 · 2022: $373 · 2023: $30.81 · 2024: $4,408 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,870 · Food and Beverage: $1,148 · Travel and Lodging: $929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,870.00 |
| Food and Beverage | $1,148.00 |
| Travel and Lodging | $928.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,559.14 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $421.00 | 2021-2025 | Xifaxan |
| Abbvie INC. | $313.70 | 2021-2025 | |
| Madrigal Pharmaceuticals | $158.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $108.58 | 2024-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $88.38 | 2021 | |
| Eisai INC. | $62.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.97 | 2021-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $46.58 | 2021-2022 | |
| Amgen INC. | $44.56 | 2021-2025 | Uplizna |
| Novo Nordisk INC | $36.00 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $30.81 | 2023 | |
| Sandoz INC. | $25.47 | 2024 | Hyrimoz |
| Alnylam Pharmaceuticals INC. | $21.63 | 2022 | |
| Lilly USA, LLC | $20.98 | 2025 | Omvoh |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.28 | 2024 | |
| Boston Scientific Corporation | $19.37 | 2025 | General - Pain Management |
| Mirum Pharmaceuticals, INC. | $17.58 | 2024 | Livmarli |
| Exelixis INC. | $17.46 | 2021 | |
| Dova Pharmaceuticals | $16.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Hepner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.